Unravelling Risk Factors for Chronic Dizziness in Patients After an Acute Unilateral Vestibular Deafferentiation. (Activation)

December 3, 2024 updated by: Lien Van Laer, Universiteit Antwerpen

Unravelling Risk Factors for Chronic Dizziness in Patients After an Acute Unilateral Vestibular Deafferentiation Syndrome.

In many patients with an acute unilateral vestibular deafferentiation (uVD) syndrome symptoms are expected to resolve spontaneously because of central compensation. However, more detailed observations have revealed that 29-66 % of uVD patients develop disabling chronic dizziness lasting >1 year after the acute event. Identifying predictors of chronic dizziness would allow patients at high risk to be targeted with personalized therapies to reduce healthcare costs. Therefore, the main objective of this study is to identify predictors of chronic dizziness after an acute uVD. Despite the consensus on the usefulness of physical therapy, incorporation of physical therapy programs in daily management of patients after acute uVD remains troublesome. Therefore, the first objective is to study the effect of the actual level of physical activity in the acute stage on long term (LT) outcome. Recent data show that LT prognosis is more linked to anxiety and somatization traits than to objective vestibular findings. Therefore, the second objective is to study the effect of activities avoidance behavior on LT outcome. As stated above it is questioned whether objective vestibular findings can predict chronicity. However recently the Perez and Rey(PR) score was developed. Therefore, the third objective is to study the effect of early central vestibular compensation as measured by the PR score on LT outcome. In patients with poor central vestibular compensation the remaining sensory cues will need to compensate for the loss of vestibular information. Patients using a visual compensation strategy can become dependent of stable visual cues. Therefore, the fourth objective is to study the effect of visual motion sensitivity on LT outcome. A 2-year prospective cohort study will be performed to study aforementioned risk factors for chronic dizziness. Up to 200 consecutive patients with an acute uVD will be included. Chronic dizziness is indicated by a score >30 on the Dizziness Handicap Inventory (primary outcome) after 6 months. Possible risk factors will be evaluated by using MOX1-activity loggers (objective 1), the Vestibular Activities Avoidance Inventory (objective 2), video Head Impulse Testing including the Perez & Rey score (objective 3), Subjective Visual Vertical test and Rod & Disc test (objective 4). Measurements will be taken in the acute phase and 4, 10, 26 and 52 weeks after the acute event.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In humans, acute unilateral peripheral vestibular dysfunction, whether by disease, accident, toxicity or iatrogenic, produces the unilateral vestibular deafferentiation (uVD) syndrome. In many patients, it resolves spontaneously and more or less completely because of central compensation. However, more detailed observations have revealed that 29-66% of uVD patients develop disabling chronic dizziness that lasts more than 1 year after the acute event, irrespective of the underlying etiology and regardless of the way the chronic complaints are documented: clinical bedside tests, vestibulo-ocular reflex(VOR) measurements, balance performance or perceived handicap. Although these chronic symptoms are not severe or life-threatening, they generate significant personal and social handicap in patients, leading to frequent consultations in general practice, Ear-Nose-Throat(ENT) and neurology clinics. A recent epidemiologic study revealed a prevalence of 6.5% of peripheral vestibular disorders in 70.315.919 patients in Germany thereby demonstrating its impact on society in a developed country. Identifying predictors of the "acute-to-chronic" dizziness transition would allow patients at high risk for developing chronic dizziness to be targeted with personalized therapies to reduce healthcare costs. In addition, up to 50% of patients with a chronic vestibular syndrome have a risk of developing depression or anxiety disorders. Therefore, the main objective of this study is to identify predictors of chronicity with a focus on investigating the effect of patients' tendency to avoid complaint-triggering movements and the actual level of physical activity on long-term outcomes in patients after acute uVD. Medical treatment in the acute phase is currently focused on symptomatic treatment with antivertiginous drugs (antihistamines) while motivating and helping patients to move as quickly as possible, an essential part of vestibular rehabilitation. There is moderate to strong evidence that vestibular rehabilitation is a safe, effective management for unilateral peripheral vestibular dysfunction, based on a number of high-quality randomized controlled trials. Furthermore, there is moderate evidence that vestibular rehabilitation resolves symptoms and improves functioning in the intermediate term but there is insufficient evidence to discriminate between different forms of vestibular rehabilitation. Based on a clinical practice guideline from the American Physical Therapy Association (Neurology Section),clinicians may offer specific exercise techniques to target identified impairments or functional limitations and may provide supervised vestibular rehabilitation. Despite the consensus on the usefulness of physical therapy, incorporation of physical therapy programs in daily management of patients after acute uVD remains troublesome. Research into health care utilization in patients with dizziness revealed a low number of visits for vestibular disorders were referred to physical therapy in ambulatory care. Moreover, the confrontation with current practice and the review of research protocols that study long-term outcome after an acute uVD show that the approach usually consists of encouraging patients to move a round as much as possible without the supervision of the physical therapist. Early and active vestibular rehabilitation is crucial. However, there are no known studies that investigate the actual physical activity level and/or exercise adherence in home exercise programs in patients with acute uVD. Therefore, our first objective is to study the effect of physical activity/movement volume in the acute stage on long term outcome after an acute uVD. Furthermore, psychological factors such as anxiety, depression and fear of falling have a negative effect on the outcome of vestibular rehabilitation. Indeed, recent data show that long-term prognosis in vestibular neuritis patients is more linked to anxiety and somatization traits than to objective vestibular findings. Pathophysiologic processes seem to include precipitating events that trigger anxiety-related changes in postural strategies with an increased attention to head and body motion and a cocontraction of leg muscles. Fear of movement in response to injury is a concept first introduced in the field of chronic low back pain, where it was shown that fear of inducing or increasing pain could lead to a maladaptive response of restricting movements and activities. In contrast, the confrontation response leads to increased movement and return to activities. This model can be translated to vestibular disorders as avoiding complaint-inducing movements is a known compensation strategy used by patients with an acute uVD. These physical activities are very important to promote compensation and avoiding them can therefore contribute to greater disability. Therefore, the second objective is to study the effect of activities avoidance behavior on long term outcome after an acute uVD. Acute uVD is defined by the patient history, the clinical examination and often characterized by measurable vestibular parameters using three-dimensional video head impulse testing (vHIT), caloric irrigation, sinusoidal harmonious acceleration testing (SHA) and cervical/ocular vestibular-evoked myogenic potentials (c/o VEMP). However, whether these VOR function measurements can predict chronicity is questioned. Recently a new tool (i.e. the Perez and Rey (PR) score) was developed to characterize the state of vestibular compensation of subjects diagnosed with acute uVD of peripheral origin. The PR score is a measure of temporal organization of the refixation saccades that enables to distinguish clearly and objectively between subjects that are in a compensated or uncompensated vestibular situation. However the PR score has never been studied as a prognostic factor of progression to chronicity. Therefore, the third objective is to study the effect of early central vestibular compensation as measured by the PR score on long term outcome after an acute uVD. Accurate perception of gravity is important for spatial orientation, postural balance, and the regulation of gait. Multiple sensory signals contribute to the central processing of this percept, including signals from visual, vestibular and somatosensory systems. Patients after an acute uVD suffer from a deteriorated sense of spatial orientation, leading to balance problems. In uncompensated vestibular patients the remaining sensory cues will need to compensate for the loss of vestibular information. Recently a reweighting of sensory signals with an increase in visual weight of 20-40% was suggested in patients with a bilateral vestibular function loss. This visual compensation strategy can make some patients dependent of stable visual cues which might lead to visual motion sensitivity. Evidence is mounting that visual field dependency is also a factor contributing to visual vertigo in patients with vestibular disorders. Visually induced dizziness or visual vertigo is a specific form of persistent perceptual postural dizziness which is classified as a chronic functional vestibular disorder. Therefore, the fourth objective is to study the effect of visual motion sensitivity on long term outcome after an acute uVD.

Study Type

Observational

Enrollment (Actual)

103

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
    • Antwerpen
      • Antwerp, Antwerpen, Belgium, 2610
        • University of Antwerp

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients with an acute unilateral vestibular deafferentiation

Description

Inclusion Criteria:

  • Acute unilateral vestibular deafferentiation

Exclusion Criteria:

  • Central pathologies and bilateral vestibulopathies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Acute unilateral vestibular deafferentiation
Patients suffering from acute dizziness due to a unilateral vestibular deafferentiation.
Other: Home exercise program
A home exercise program is provided but this is an observational study. The effect of the exercise program is not under investigation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dizziness Handicap Inventory
Time Frame: 6 months
Questionnaire concerning impairments due to dizziness: the higher the score, the bigger the perceived handicap due to dizziness.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perez-and Rey score
Time Frame: Week 1, 4, 10, 26 & 52
Temporal organisation of corrective saccades
Week 1, 4, 10, 26 & 52
Mox1loggers
Time Frame: Week 1 & 10
Level of physical activity
Week 1 & 10
Rod&Disc test
Time Frame: Week 10 & 26
Visual dependency
Week 10 & 26
Anxiety
Time Frame: Week 1, 4, 10, 26 & 52
Hospital Anxiety and Depression Scale: two subscales (anxiety and depression). A lower score means less chance on an anxiety or depression disorder.
Week 1, 4, 10, 26 & 52
Avoidance behavior
Time Frame: Week 1, 4, 10, 26 & 52
Vestibular Activities Avoidance Inventory: the higher the score, the bigger the chance that avoidance behavior is present.
Week 1, 4, 10, 26 & 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Universiteit Antwerpen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 3, 2021

Primary Completion (Actual)

October 30, 2024

Study Completion (Actual)

November 1, 2024

Study Registration Dates

First Submitted

July 6, 2021

First Submitted That Met QC Criteria

July 16, 2021

First Posted (Actual)

July 28, 2021

Study Record Updates

Last Update Posted (Estimated)

December 5, 2024

Last Update Submitted That Met QC Criteria

December 3, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 42186

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

A registration at the Research Database Antigoon was submitted and approved. In this way a Data Protection Impact Assessment (DPIA) is performed. A Data Management was published on "dmponline.be".

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Unilateral Vestibular Deafferentiation

Clinical Trials on Home exercise program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe